Glycemic control in young type 1 diabetic patients is a mission that usually perturbs the clinicians. The frequently encountered physical (body composition and hormonal variations), environmental stress (challenges due to family, society, work, and friends) and emotional factors affect insulin requirements of the individuals. Glucose fluctuation, hypoglycemia and weight gain are difficult to avoid during multiple daily injections (MDI) of insulin treatment [1] .
and episodic insulin adjustment [2] . However, CSII is expensive and its long-term benefits have been still controversial [3, 4] . Moreover, in the daily practice the initial CSII use in outpatient setting is not as easy as multiple daily injections (MDI).
On the other hand, good glucose control depends on meticulous monitoring of blood glucose levels in diabetic patients. Continuous glucose monitoring (CGM), when compared to self-monitoring of blood glucose (SMBG), provides better measurement of continuous glucose levels and excursions [5, 6] . Similar to CSII, its use is limited by the cost of its implementation.
Based on these issues, we designed a program by short-term intensive treatment of CSII plus CGM to reinforce the treatment outcome in young adult pumpnaïve type 1 diabetic patients.
Intensive insulin adjustment
The insulin regimen was switched from MDI to CSII according to a previously described protocol [5, 7] . In short, 75% of the MDI total daily insulin was used as the starting dose of CSII to avoid possibly hypoglycemia. Half of them were infused continuously as the basal dose and the other half was divided for each meal as the bolus dose. The basal insulin dose was then titrated precisely as small as 0.1 IU per hour to maintain the blood glucose targets in the range of 90-140 mg/dL from bedtime through the nocturnal period and 70-140 mg/dL before each meal. The bolus insulin dose was titrated up or down cautiously with 1 IU every time for the fixed carbohydrate amount to keep postprandial glucose ranges between 70 and 180 mg/ dL ( Fig. 1 ). We found the setting of 50% of total daily dose as basal insulin was usually overestimated in our patients. Therefore, we could simply focus on reducing the basal infusion rate to prevent hypoglycemia and increasing bolus dosage for the fixed carbohydrate amount at meals. Most of our patients received an adequate adjustment based on this 3-day's titration protocol. At the end of the study, the switch in treatment of MDI from CSII was equal to the total daily basal dose and respective pre-meal bolus according to the recommended protocol [8] . The medical team including diabetologists, educators, and dieticians was on call steadily to manage any unexpected conditions.
Data collection
The MiniMed Solutions: CGMS sensor MMT-7310 Version 3.0B (3.0.116) was introduced to download the CGMS data after the study. The glucose variability was defined as the standard deviation of plasma glucose (SDPG) [9] and the mean amplitude of glucose excursion (MAGE) [10] of all glucose values for 3 days. The area under the curve of a glucose level above 180 mg/dL (AUC >180 ) and below 70 mg/dL (AUC <70 ) was calculated for hyperglycemic and hypoglycemic periods respectively. A hypoglycemic event was defined as a glucose concentration below 70 mg/dL. Information recorded between 0000 and 0600 hours was defined as nocturnal occurrence. The total daily dose of insulin was defined as the sum of the basal and bolus insulin. Bolus insulin was defined as the sum of daily pre-meal and correction doses of insulin Aspart.
Statistical analysis
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Subjects
Twenty-six young adult type 1 diabetic patients consecutively treated at Chang Gung Memorial Hospital Diabetes Center between 2007 and 2009 were enrolled for the combined CSII and CGM program. The study was approved by the institutional review board. Patients needed to meet all the following criteria: (a) age of ≥ 18 years, (b) a very low C-peptide level (<0.35 ng/mL) with or without the experience of diabetic ketoacidosis, (c) pump-naïve, and (d) ambulatory and willing to cooperate during the program. The patients were told that they have to stop using CSII at the end of study. Informed consent was obtained from each subject. Twenty-three patients were treated with multiple daily injections with insulin Glargine (Sanofi Aventis) or Determir (Novo Nordisk) as basal, and insulin Aspart (Novo Nordisk) as bolus at least 3 times a day. Three patients received premixed insulin Novomix 30/70 (Novo Nordisk) injections twice a day.
Short-term CGM and CSII program
Initially, a 3-day professional CGM (CGMS, Medtronic MiniMed Inc., Northridge, CA, USA; nonreal-time device) (I) was used to evaluate the baseline glycemic control status of the subjects. The CGMS detected interstitial fluid glucose concentration every 10 seconds and an average glucose value was provided every 5 minutes (i.e., 288 measurements per day). A 6-day CSII (MiniMed Paradigm 712 pump, Medtronic MiniMed Inc., Northridge, CA, USA) course was then designed for intensive insulin adjustment. This CSII course consisted of 2 phases. In the first phase (3 days) patients were admitted to the ward and capillary blood glucose was measured 8 times per day (3 preprandial and 3 postprandial periods, at bedtime, and at 0300 hours) for insulin dosing calibration. Patients were discharged and kept their normal daily routine in the second phase (last 3 days), with another 3-day CGMS (II) performed in conjunction with CSII to survey the effectiveness of the outcomes. All patients were carefully instructed to operate the CSII and CGMS till they could adept and handle the machines.
Twelve weeks after the study program, all patients returned to record clinical parameters and measure their serum HbA1c levels.
6.9 ± 0.9 to 3.7 ± 0.5 (p = 0.003). The hypoglycemic events during nocturnal periods were significantly minimized (1.9 ± 0.4 vs. 0.7 ± 0.1, p = 0.002).
Through the intensive insulin adjustment provided by CSII, as shown in Table 3 , the requirement of total daily insulin decreased 28.05% (0.82 ± 0.04 vs. 0.59 ± 0.03 IU/kg, p < 0.001) in our participants. This decrease was noted in basal as well as bolus insulin (0.30 ± 0.02 vs. 0.23 ± 0.01 IU/kg, −23.33%, p = 0.001 were tested using a paired Student's t-test. Differences in proportions were assessed using a chi-square test or Fisher's exact test, as indicated. Results were expressed as means ± SD or %. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS for Windows, Version 16.0) software, and the level of statistical significance was set at a p-value of 0.05 or less.
Results
The mean age of the patients enrolled in this study was 33 years old and the mean history of diabetes was thirteen years ( Table 1 ). The female to male ratio was 8:2. The frequency of having retinopathy, nephropathy, and neuropathy among these patients was 38.5%, 15.4%, and 7.7%, respectively.
The patients' blood glucose levels were assayed before and after the CSII program. Blood glucose changes between the first and second CGM are summarized in Table 2 . Glucose variability decreased by 23.3% in SDPG (67.8 ± 2.7 to 52.0 ± 1.8 mg/dL, p < 0.001) and 24.9% in MAGE (140.4 ± 6.5 to 105.5 ± 5.3 mg/dL, p < 0.001). The AUC >180 and AUC <70 declined significantly (−35.1%, p = 0.032 and −87.0%, p < 0.001, respectively), indicating a decreased frequency of both hyper-and hypoglycemic periods. The hypoglycemic events across 3 days were reduced from control for type 1 diabetic young patients with MDI therapy. Through the program, glucose variability was reduced by 23.3% and 24.9% in SDPG and MAGE, respectively. A significant 46% prevention of hypoglycemia was noted. The insulin requirement was substantially reduced by 28.1%. Implementation of this novel program can provide practical resolution in current obstacles of type 1 diabetic management.
The Diabetes Control and Complications Trial (DCCT) [11] and Epidemiology of Diabetes Interventions and Complications (EDIC) [12] have demonstrated that intensive blood glucose control reduces the risk of both micro-and macrovascular complications in patients with type 1 diabetes mellitus. However, it is very difficult to keep blood glucose levels as close to normal as possible in the majority of patients. In the DCCT, patients with multiple daily injections (MDI) of insulin were prone to develop symptomatic hypoglycemic events and weight gain during long-term insulin treatment [1] .
Hypoglycemia is a major threat for patients with diabetes, not only physically, but also psychologically. and 0.53 ± 0.03 vs. 0.36 ± 0.02 IU/kg, −32.08%, p < 0.001, respectively).
The insulin responsiveness of patients demonstrated as AUC of blood glucose to per IU insulin showed a 32.1 % increase following the program (2.8 ± 0.3 vs. 3.7 ± 0.3 mg/dL × 24h/IU, p = 0.002) ( Table 3) .
After the program, 2 patients accepted CSII as their daily treatment. The other 24 patients received a new regimen of MDI. At the 12-week follow-up, the mean HbA1c declined from 8.8% at baseline to 8.4% (p = 0.036). There were no significant changes recorded in lipid profiles, albuminuria values, or neuropathy detection (data not shown). The body weight (BW) and body mass index (BMI) also had no significant changes at 12 weeks (BW from 58.8 to 58.3 kg with p = 0.188 and BMI from 22.2 to 22.0 with p = 0.167, respectively). All participants expressed acceptance of the program.
Discussion
Our data demonstrated that a short-course CSII as a reinforcing program provided advantages in glucose requirement for our patients. The 32% improvement of insulin effectiveness manifested as AUC of blood glucose to per IU insulin (Table 3 ) might be related to the reduction of hypoglycemic events and the adjustment of the basal and bolus insulin proportion. Our program involves not just wearing the external devices but also having the support of an interdisciplinary team and intensive patient education. Through this practical program, patients can improve the ability to capture their own problems and provide solutions to the difficulties in daily routine insulin treatment. In this study cohort, we cannot exclude the educational effects. But the value of this study is the disclosure of many hypoglycemic events and inappropriate insulin dosing in this population. We observed that our young patients tend to have an accumulation of insulin overdose during a long period of MDI and SMBG treatment. Although the HbA1c values at the 3-month follow-up had not reached a satisfactory level (mean 8.4%), it was notable that the insulin dosage had already reduced significantly. We believed that through the reduction of insulin dosing, we avoided many hypoglycemic events and therefore, reduced the glucose excursion. Whether this adjuvant therapy needs to be performed periodically still needs further evaluation.
In conclusion, a short-course CSII program is easily accepted and affordable as adjuvant therapy for type 1 diabetic young adults undergoing MDI therapy. It effectively corrects insulin dosage, prevents most hypoglycemic events and reduces glucose variability.
A reduction in hypoglycemic events may significantly improve the life quality of type 1 diabetic patients. Short-course CGM evaluation in our study demonstrated its usefulness in hypoglycemic event detection. Nevertheless, sustained use of CGM has not yet been shown to be beneficial in the reduction of A1C when compared with SMBG [13] . A 28% reduced insulin requirement might be the major factor attributed to the reduction of hypoglycemic events.
Chronic hyperglycemia is a known risk among diabetic complications [11, 12, 14] . In addition to fasting hyperglycemia, postprandial hyperglycemia is an independent risk factor for macrovascular diseases [15] . Monnier and his associates demonstrated that acute glucose fluctuation is associated with oxidative stress to the endothelium [16] and therefore may contribute to chronic complications. Although the impact of glycemic variability on chronic complications is not clear [9, 17] , it is prudent to reduce blood glucose fluctuations while treating diabetic patients [18] . A reduction in glucose swings, as was found with the CSII program, might provide benefits beyond improvement of HbA1c levels. Table 3 demonstrated that both basal and bolus insulin doses were decreased (23.33% and 32.08%, respectively) following the program. These results supported the suggestion that the CSII reinforcement program was effective. Our data also indicated that the estimated insulin requirement of type 1 diabetic young adults in Taiwan was 0.6 IU/kg per day, in a proportion of which 40% was given as basal and 60% as bolus insulin. This is a relatively low basal insulin proportion compared to the 50% found in other studies [4, 5, 7] . Rice-based meal contents and low fatty food in the typical diet in Taiwan are the possible explanations of this phenomenon. The relative low BMI (22.2 in average) may also require lesser proportion of basal insulin
